These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37564537)

  • 1. Retracted: Effects of Fufang Banmao Capsule Associated with Sorafenib on Liver Function, Immune Status, Quality of Life Improvement, and Survival in Patients with Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study.
    Intelligence And Neuroscience C
    Comput Intell Neurosci; 2023; 2023():9817406. PubMed ID: 37564537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Proteomic analysis of differentially expressed proteins in human hepatoma SMMC-7721 cells induced by Fufang Banmao capsule serum].
    Cao YY; Wang M; Huang KS; Yang Q; Ding M
    Zhongguo Zhong Yao Za Zhi; 2007 May; 32(9):831-4. PubMed ID: 17639987
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Liu Y; Li Y; Wang X; Huang Y; Zhang Q; Shi K; Ran C; Hou J; Wang X
    J Altern Complement Med; 2020 Oct; 26(10):956-965. PubMed ID: 32614605
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of adjuvant traditional Chinese medicine therapy on long-term survival in patients with hepatocellular carcinoma.
    Liu X; Li M; Wang X; Dang Z; Yu L; Wang X; Jiang Y; Yang Z
    Phytomedicine; 2019 Sep; 62():152930. PubMed ID: 31128485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment.
    Shomura M; Kagawa T; Okabe H; Shiraishi K; Hirose S; Arase Y; Tsuruya K; Takahira S; Mine T
    BMC Cancer; 2016 Nov; 16(1):878. PubMed ID: 27835949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis.
    McNamara MG; Slagter AE; Nuttall C; Frizziero M; Pihlak R; Lamarca A; Tariq N; Valle JW; Hubner RA; Knox JJ; Amir E
    Eur J Cancer; 2018 Dec; 105():1-9. PubMed ID: 30384012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
    Abdel-Rahman O; Elsayed Z
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011313. PubMed ID: 31978267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007-2015.
    Huang CC; Chen HY; Chang RH; Liao PA; Lien HH; Hung CS; Yang SS; Hu JT
    Drug Des Devel Ther; 2019; 13():397-404. PubMed ID: 30774305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retracted: Studying the Role and Molecular Mechanisms of
    International BR
    Biomed Res Int; 2024; 2024():9760191. PubMed ID: 38550169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
    Jouve JL; Lecomte T; Bouché O; Barbier E; Khemissa Akouz F; Riachi G; Nguyen Khac E; Ollivier-Hourmand I; Debette-Gratien M; Faroux R; Villing AL; Vergniol J; Ramee JF; Bronowicki JP; Seitz JF; Legoux JL; Denis J; Manfredi S; Phelip JM;
    J Hepatol; 2019 Sep; 71(3):516-522. PubMed ID: 31125576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy.
    Yeh ML; Kuo HT; Huang CI; Huang CF; Hsieh MY; Liang PC; Lin IH; Hsieh MH; Lin ZY; Chen SC; Dai CY; Huang JF; Yu ML; Chuang WL
    Kaohsiung J Med Sci; 2021 Feb; 37(2):145-153. PubMed ID: 33022892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study.
    Hayashi T; Yamashita T; Terashima T; Suda T; Okada H; Asahina Y; Hayashi T; Hara Y; Nio K; Sunagozaka H; Takatori H; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S
    BMC Cancer; 2017 Dec; 17(1):870. PubMed ID: 29258450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver stiffness in magnetic resonance elastography is prognostic for sorafenib-treated advanced hepatocellular carcinoma.
    Kim B; Kim SS; Cho SW; Cheong JY; Huh J; Kim JK; Lee JH; Ahn HR; Cho HJ
    Eur Radiol; 2021 Apr; 31(4):2507-2517. PubMed ID: 33033862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
    Saab S; McTigue M; Finn RS; Busuttil RW
    Exp Clin Transplant; 2010 Dec; 8(4):307-13. PubMed ID: 21143097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma.
    Ricke J; Schinner R; Seidensticker M; Gasbarrini A; van Delden OM; Amthauer H; Peynircioglu B; Bargellini I; Iezzi R; De Toni EN; Malfertheiner P; Pech M; Sangro B
    J Hepatol; 2021 Dec; 75(6):1387-1396. PubMed ID: 34454995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.
    Ricke J; Klümpen HJ; Amthauer H; Bargellini I; Bartenstein P; de Toni EN; Gasbarrini A; Pech M; Peck-Radosavljevic M; Popovič P; Rosmorduc O; Schott E; Seidensticker M; Verslype C; Sangro B; Malfertheiner P
    J Hepatol; 2019 Dec; 71(6):1164-1174. PubMed ID: 31421157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
    Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
    Trials; 2014 Dec; 15():474. PubMed ID: 25472660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.
    Sanoff HK; Chang Y; Lund JL; O'Neil BH; Dusetzina SB
    Oncologist; 2016 Sep; 21(9):1113-20. PubMed ID: 27185615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.